



# RESET T1D

Type 1  
Diabetes  
TrialNet

A study for those newly diagnosed with T1D

## About RESET T1D

TrialNet is studying **repegaldesleukin** to learn if it can help people newly diagnosed with type 1 diabetes (T1D) keep making their own insulin by stimulating regulatory T cells to restore immune balance.

Repegaldesleukin is already being studied in people with other autoimmune diseases like psoriasis and eczema. This is the first time it is being studied in people with T1D.

66 participants will receive an injection (shot) of repegaldesleukin or placebo (inactive version of the study drug) every 2 weeks for 6 months.

## Who May Be Able to Participate?

- Newly diagnosed with T1D (in the past 3 months)
- Between age 18 and 45

**Younger ages may be allowed later in the study.**

**For current ages enrolling, check here:**

[trialnet.org/reset-t1d](https://trialnet.org/reset-t1d)



## TrialNet Locations

This study is open to people who live in a country with a participating TrialNet site. Travel assistance is available, if needed, to help get you to the nearest location.

## Study Features



**Every 2 weeks** you will visit a study site to receive an injection, have blood tests, and be closely monitored.



You will **wear a continuous glucose monitor (CGM)** for 7 days after some study visits. If you don't have a CGM, we will provide one.

## Randomized



**2 out of 3 people** get repegaldesleukin.

1 out of 3 people will get a placebo.

A computer randomly selects who gets the study drug.

## Measuring Insulin Production

C-peptide tests will measure the study drug's impact on insulin production. This test shows how much insulin the body is making on its own, even when it is getting insulin from injections or a pump.



# RESET T1D

Type 1  
Diabetes  
TrialNet

## Study Enrollment Timeline

Because this is the first time rezpegaldesleukin is being tested in people with T1D, the study enrolls participants in small groups by age. It is estimated that it will take 3 years to enroll all groups.

### Enrolls first

**Group A: AGES 18 - 45**



### Enrolls second

**Group B: AGES 12+**



### Enrolls third

**Group C: AGES 8+**

 *Reviews will occur before younger ages can be allowed in the study.*

## Participant Experience

Participation in the study lasts for 1 year beginning with the treatment phase and ending after the follow-up phase.

## 1 Year in the RESET T1D Study

### Eligibility Visit



#### Consent

Review and agree to study requirements



#### ECG

Electrocardiogram to test your heart



#### MMTT

Drink a liquid meal and have blood draws



#### CGM

Continuous glucose monitor

Before you join the study, the TrialNet research team will explain the study in detail, including risks and benefits, and answer all your questions.

### Contact TrialNet

[info@trialnet.org](mailto:info@trialnet.org)  
1-800-425-8361

## Treatment Visits (6 months)

Every 2 weeks you will receive an injection at a study visit. In the treatment phase, there are 15 study visits in 6 months.

## Follow-Up Visits (6 months)

In the follow-up phase, you will have 3 study visits spread over the remaining 6 months.

*When your participation in RESET T1D ends, you can join the LIFT Study for continued monitoring.*

**Sign up for the study here:**  
[trialnet.org/reset-t1d](https://trialnet.org/reset-t1d)

